Risk of Pancreatic Problems with Different Diabetes Medicines in Adults with Type 2 Diabetes and Moderate Heart Disease Risk

Disclosure In the last 36 months, R.G.M. has received unrelated research support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institute of Health (NIH), the National Institute on Aging (NIA) of the NIH, the National Center for Advancing Translational Sciences (NCATS), and the American Diabetes Association (ADA). R.G.M. also served as a consultant to EmmiEducate (Wolters Kluwer) and the Yale-New Haven Health System and received speaking honoraria and travel support from the ADA. J.H. currently receives unrelated research support from the Centers for Medicare and Medicaid Services, the NIH, Agency for Healthcare Research and Quality (AHRQ), Patient-centered Outcomes Research Institute (PCORI), and the American Heart Association (AHA) (all unrelated to this work). J.J.N. receives unrelated research support from the NIH and the American College of Clinical Pharmacy; serves as a consultant to Bayer, Eli Lilly, Boehringer Ingelheim, and Proteomics International; and received other support from the ADA (all unrelated to this work). R.J.G. receives unrelated research supported by the NIH, Novo Nordisk, Dexcom, and Eli Lilly and consulting/advisory/honoraria fees from Abbott, Dexcom, Eli Lilly, Novo Nordisk, Bayer, Boehringer, Medtronic, and AstraZeneca, outside of this work. G.E.U. is partly supported by unrelated research grants from the NIH, Bayer, Abbott, and Dexcom and has served as a member of advisory boards for Dexcom, Corcept, and GlyCare Health, all unrelated to this work. J.S.R. currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program, AHRQ, and Arnold Ventures; J.S.R. formerly received research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST). In addition, J.S.R. was an expert witness at the request of Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc that was settled in September 2022. The other authors have no conflicts of interest to disclose.